Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.47 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.47 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL6753488 | 0.96 | CA4 (0.44) | CA4OR51E2GLRA1SLC6A9CASP1 | |
| Glycine SCHEMBL2916896 | 0.96 | CA4 (0.50) | CA4OR51E2GLRA1SLC6A9CASP1 | |
| Glycine SCHEMBL8149628 | 0.92 | — | — | |
| Glycine SCHEMBL5712834 | 0.92 | CA4 (0.47) | CA4OR51E2GLRA1SLC6A9CASP1 | |
| Glycine SCHEMBL33936 | 0.92 | CA4 (0.47) | CA4OR51E2GLRA1SLC6A9CASP1 | |
| Glycine SCHEMBL22948 | 0.92 | — | — | |
| Glycine SCHEMBL7199765 | 0.92 | — | — | |
| Glycine SCHEMBL7632674 | 0.92 | CA4 (0.47) | CA4OR51E2GLRA1SLC6A9CASP1 | |
| Glycine SCHEMBL21747591 | 0.92 | CA4 (0.47) | CA4OR51E2GLRA1SLC6A9CASP1 | |
| Glycine SCHEMBL1633657 | 0.92 | CA4 (0.47) | CA4OR51E2GLRA1SLC6A9CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117179152-B | Multi-mineral feed additive and preparation method thereof | 山东美事达农牧科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-118141108-A | Mineral ion liquid and application thereof in preparation of products with diabetes treatment effect | 广州唯纳大健康产业科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-117179152-A | Multi-mineral feed additive and preparation method thereof | 山东美事达农牧科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-112028782-B | Production system and method of glycine complex chromium salt | 重庆森乐美生物科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-20220296533-A1 | COMPOSITIONS AND METHODS FOR INCREASING INTRACELLULAR GLUCOSE UPTAKE | EXCROMBIO LLC | 2022-09-22 | — | — | US | claimed |
| US-20220273705-A1 | Method for the Reduction of Dangerous Blood Sugar Levels | RUSS IP HOLDING GROUP LLC | 2022-09-01 | — | — | US | claimed |
| US-20210346334-A1 | NUTRITIONAL CHROMIUM COMPOSITIONS AND METHODS OF USE | RUSS IP HOLDING GROUP LLC | 2021-11-11 | — | — | US | claimed |
| US-20210330752-A1 | FEED SUPPLEMENTS | OMNIGEN RESEARCH, LLC (US) | 2021-10-28 | — | — | US | claimed |
| WO-2020142305-A1 | FEED SUPPLEMENTS | OMNIGEN RESEARCH, LLC (US) | 2020-07-09 | — | — | WO | claimed |
| US-20170202244-A1 | COMPOSITIONS AND COMBINATIONS FOR USE AS FOOD SUPPLEMENTS FOR ANIMALS | OMNIGEN RESEARCH, LLC (US) | 2017-07-20 | — | — | US | claimed |
| US-20040157895-A1 | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | ARCTURUS BIOSCIENCE, INC. | 2004-08-12 | — | — | US | claimed |
| US-6686340-B2 | ADMINISTERING A VITAMIN (ASCORBIC ACID), AN AMINO ACID (ARGININE) AND A TRACE ELEMENT (MAGNESIUM) FOR TREATMENT OF HIGH BLOOD PRESSURE, ASTHMA, GLAUCOMA AND TINNITUS | Rath, Matthias | 2004-02-03 | — | — | US | claimed |
| EP-1324753-A2 | COMPOSITIONS AND METHODS FOR LOWERING PLASMA LIPOPROTEIN(A) AND RISK FACTORS OF CARDIOVASCULAR DISEASES | Rath, Matthias (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030003162-A1 | Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells | RATH MATTHIAS (US) | 2003-01-02 | — | — | US | claimed |
| US-20020094996-A1 | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | RATH MATTHIAS (NL) | 2002-07-18 | — | — | US | claimed |
| WO-2002028379-A2 | COMPOSITIONS AND METHODS FOR LOWERING PLASMA LIPOPROTEIN(A) AND RISK FACTORS OF CARDIOVASCULAR DISEASES | RATH MATTHIAS (US) | 2002-04-11 | — | — | WO | claimed |
| CN-1333020-A | Biochemical substance as composition for preventing and treating health-affecting diseases caused by smooth muscle cell contraction in human organs | MASERS LAS (US) | 2002-01-30 | — | — | CN | claimed |
| EP-1163904-A1 | Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium | Rath, Matthias, Dr. med. (NL) | 2001-12-19 | — | — | EP | claimed |
| US-6248323-B1 | CULTURE PRODUCT; INCUBATION; ISOLATION; PASTEURIZATION | VIVA LIFE SCIENCE, INC. | 2001-06-19 | — | — | US | claimed |
| US-6159466-A | Aqueous composition comprising saccharomyces boulardii sequelaand chromium glycinate dinicotinate | VIVA AMERICA MARKETING, INC. (US) | 2000-12-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296533-A1 | COMPOSITIONS AND METHODS FOR INCREASING INTRACELLULAR GLUCOSE UPTAKE | SLC2A4, SLC2A1, SLC2A3 | CA4 709/4885OR51E2 4651/4885GLRA1 798/4885 |
| US-20210330752-A1 | FEED SUPPLEMENTS | IGFBP6, CHI3L2, IGFBP3 | CA4 626/4885OR51E2 748/4885GLRA1 4173/4885 |
| US-20210346334-A1 | NUTRITIONAL CHROMIUM COMPOSITIONS AND METHODS OF USE | SLC5A6, SLC5A2, GART | CA4 262/4885OR51E2 3910/4885GLRA1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.